Background {#Sec1}
==========

Rheumatoid arthritis (RA) affects approximately 0.5--1% of the U.S. general adult population \[[@CR1]--[@CR3]\]. Patients with RA have both articular and extraarticular manifestations, such as accelerated cardiovascular disease (CVD), which accounts for up to 50% of the deaths in this population \[[@CR4], [@CR5]\]. The cardiovascular morbidity and mortality are hypothesized to be due in part to persistent systemic inflammation; however, the exact mechanisms remain undetermined. Unfortunately, traditional cardiac risk factors seen in the normal population do not completely account for this increase in CVD in RA, a prototypical rheumatic disease \[[@CR6], [@CR7]\]. There is a great unmet need to identify nontraditional molecular biomarkers and related pathways responsible for the higher CVD incidence in patients with RA.

[l]{.smallcaps}-arginine is the common substrate of nitric oxide synthase (NOS) and arginases \[[@CR8]\]. NOS catalyzes [l]{.smallcaps}-arginine to generate nitric oxide (NO) and [l]{.smallcaps}-citrulline, whereas arginases catalyze the conversion of [l]{.smallcaps}-arginine to [l]{.smallcaps}-ornithine and urea (Fig. [1a](#Fig1){ref-type="fig"}). Elevated arginase activity therefore can diminish the bioavailability of [l]{.smallcaps}-arginine by substrate competition and decrease NO production, which can lead to endothelial dysfunction \[[@CR9], [@CR10]\] and eventually result in adverse cardiovascular issues \[[@CR11]\]. An additional level of regulation in NO production is mediated by methylated arginine products [l]{.smallcaps}-*N*^G^-monomethyl arginine (MMA), asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA) (Fig. [1b](#Fig1){ref-type="fig"}). MMA and ADMA are potent endogenous inhibitors of NOS, whereas SDMA inhibits NO production mainly by blocking the cellular uptake of [l]{.smallcaps}-arginine \[[@CR12]\]. The role of elevated ADMA in inducing endothelial dysfunction has been studied extensively \[[@CR13]--[@CR15]\]; however, the role of SDMA in CVD pathogenesis is not well understood. Importantly, our group and others have demonstrated that elevated plasma levels of both ADMA and SDMA are associated with increased risk for CVD in the general population \[[@CR14], [@CR16]--[@CR19]\].Fig. 1Urea cycle and dimethylarginine metabolic pathways. **a** [l]{.smallcaps}-Arginine is the common substrate of arginase and nitric oxide synthase (NOS). Asymmetric dimethylarginine (ADMA) and [l]{.smallcaps}-*N*^G^-monomethyl arginine (MMA) are potent inhibitors of NOS, whereas symmetric dimethylarginine (SDMA) inhibits nitric oxide (NO) production by inhibiting [l]{.smallcaps}-arginine cellular uptake. **b** Schematic diagram showing the pathways that produce methylated arginines (MMA, ADMA, and SDMA). *PRMT* Protein arginine methyltransferase

Despite emerging data showing a relationship between specific [l]{.smallcaps}-arginine metabolites and CVD in respective RA cohorts, a comprehensive study evaluating the arginine metabolome in a single RA cohort has not been performed. In the present study, we studied a panel of plasma [l]{.smallcaps}-arginine metabolites representing NO metabolism and plasma arginase activity in patients with RA compared with age- and sex-matched healthy control subjects. In addition, we examined associations of CVD risk factors in RA with (a) [l]{.smallcaps}-arginine metabolites; (b) global arginine bioavailability ratio (GABR; the ratio of [l]{.smallcaps}-arginine to [l]{.smallcaps}-ornithine + [l]{.smallcaps}-citrulline), which reflects overall status of [l]{.smallcaps}-arginine catabolism \[[@CR20]\]; and (c) arginine methylation index (ArgMI). ArgMI is an overall gauge for posttranslational methylation of arginine (i.e., ADMA + SDMA/MMA), which we found to be potentially a better predictor of CVD than free methylated arginines \[[@CR17], [@CR20]\].

Methods {#Sec2}
=======

Patient cohort {#Sec3}
--------------

In our cross-sectional study, patients with RA diagnosed by a board-certified rheumatologist were sequentially selected from the Cleveland Clinic Department of Rheumatic and Immunologic Diseases outpatient rheumatology clinics. Plasma samples were obtained under a protocol approved by the institutional review board (IRB) of the Cleveland Clinic, and all participants gave written informed consent. Associated clinical data and standard of care laboratory values were collected from the patient's medical records into a de-identified, IRB-approved biospecimen registry. Clinical information collected on the RA disease cohort included body mass index; RA disease duration; RA disease activity (Disease Activity Score in 28 joints \[DAS28\]); seropositivity status; disease-modifying antirheumatic drug treatment; and CV risk factors, including history of diabetes mellitus, systolic hypertension, dyslipidemia, smoking, and prior history of CVD (defined as myocardial infarction, stroke, coronary artery disease, congestive heart failure, or valvular disease and replacement). Laboratory data included C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) values. Patients were determined to be seropositive on the basis of a rheumatoid factor \> 20 IU/ml or cyclic citrullinated peptide autoantibody level \> 20 U.

Measurement of [l]{.smallcaps}-arginine and [l]{.smallcaps}-arginine derivatives {#Sec4}
--------------------------------------------------------------------------------

Plasma samples from 119 nonfasting patients with RA and 238 nonfasting control subjects were obtained under a protocol approved by the Cleveland Clinic IRB. Plasma aliquots were isolated from whole blood collected in ethylenediaminetetraacetic acid-containing tubes that maintained at 0 °C to 4 °C immediately after phlebotomy, processed within 4 hours of blood draw, and stored at − 80 °C until use. Plasma concentrations of [l]{.smallcaps}-arginine, its metabolites ([l]{.smallcaps}-ornithine and [l]{.smallcaps}-citrulline), and methylated arginine byproducts (MMA, ADMA, and SDMA) were quantified as described in an earlier publication \[[@CR17]\]. Briefly, 4 vol of methanol-containing, isotope-labeled internal standards were added to 1 vol of plasma to precipitate protein. The supernatant after centrifugation was analyzed by injection onto a silica column interfaced with an API 4000 Q-TRAP mass spectrometer (AB SCIEX, Framingham, MA, USA). A discontinuous gradient was generated to resolve the analytes by mixing solvent A (0.1% propionic acid in water) with solvent B (0.1% acetic acid in methanol) \[[@CR21]\]. Analytes and the isotope-labeled internal standards were monitored by positive multiple reaction mode MS using characteristic precursor--product ion transitions. The parameters for the ion monitoring were optimized for each analyte. Various concentrations of analytes were titrated with control plasma sample to prepare the calibration curves.

Plasma arginase activity {#Sec5}
------------------------

We measured plasma arginase activity in 119 patients with RA and compared it with that of 148 age- and sex-matched control subjects. Plasma arginase activity was measured using the QuantiChrom Arginase Assay Kit (BioAssay Systems, Hayward, CA, USA) according to the manufacturer's instructions. Briefly, 5 μl of the plasma was diluted to 40 μl with deionized water (1:8 sample dilution), or 40 μl of deionized water (blank) was treated with kit-provided substrate containing reaction mixture, and then incubated at 37 °C for 2 hours. Arginase-catalyzed urea was measured by colorimetry after adding kit-provided reagents. The optical density was measured at 430 nm. Urea (1 mM) was used as the standard. Arginase activity (expressed as U/L of sample) was calculated. One unit of arginase converts 1 μmol of [l]{.smallcaps}-arginine to ornithine and urea per minute at pH 9.5 and 37 °C.

Statistical analysis {#Sec6}
--------------------

Descriptive summaries of demographic and clinical variables for patients with RA are provided. These include sex, medical history, medications, RA disease activity measures, CVD risk assessments, and laboratory parameters such as traditional systemic inflammatory markers. Categorical variables were compared using Pearson's chi-square test or Fisher's exact test, and continuous variables were compared using the *t* test, analysis of variance, or their nonparametric analogues, as appropriate based on distributional assumptions.

Plasma levels of [l]{.smallcaps}-arginine and its derivatives are reported for subjects with RA and age- and sex-matched healthy control subjects by means and SDs or by medians within IQRs, as appropriate (primarily based on normalized vs. skewed distribution of the data, respectively). Multivariable logistic regression models are used to estimate the ORs associated with various [l]{.smallcaps}-arginine metabolites among RA and control subjects. Correlations between [l]{.smallcaps}-arginine, its derivatives' levels, and a broad range of arthritic, inflammatory, and CV parameters were assessed using Spearman's correlation. *p* \< 0.05 was considered statistically significant. All statistical analyses were performed using R version 3.1.0 (R Core Team, Vienna, Austria).

Results {#Sec7}
=======

Study population {#Sec8}
----------------

Our cohort consisted of 119 patients with RA (84% female, mean age 60.6 ± 13.4 yr) and 238 control subjects (82% female, mean age 59 ± 13.9 yr). A subgroup of patients with RA (*n* = 33, 27.7%) from this cohort had a DAS28 assessment at the time of sampling with a median DAS28 score of 2.7 ± 1.2, 2.6 (1.6--3.5). Mean disease duration was 11.7 ± 9.6 years with low median CRP (mg/dl) of 1.2 ± 2.6, 0.4(0.2--0.9) and ESR (mm/h) of 21.3 ± 18.3, 14.5 (7--29.2) (Table [1](#Tab1){ref-type="table"}). This patient population also had a significant history of CVD risk factors, including diabetes, dyslipidemia, and hypertension at 18%, 47%, and 60%, respectively. Patients with a prior history of CVD represented 14% of the population.Table 1Clinical characteristics of subjects with rheumatoid arthritis (*n* = 119)DemographicsValuesDemographics Male sex19 (16%) Age, years60.6 ± 13.4, 62.0 (53.5--70.5) BMI, kg/m^2^28.8 ± 6.3, 28.0 (25--32)Disease activity Seropositive RA\*\*85 (71.4%)  RF+ (≥ 20)75 (63.0%)  CCP+ (≥ 20)59 (49.6%) Disease duration, yr11.7 ± 9.6, 9.0 (5--16) DAS282.7 ± 1.2, 2.6 (1.6--3.5)CV burden assessments Diabetes mellitus21 (17.6%) Hypertension71 (59.7%) Dyslipidemia56 (47.1%) Prior CV disease history17 (14.3%) Smoking (current)57 (47.9%)Medications Statin use32 (26.9%) Steroid use54 (45.4%) Methotrexate use64 (53.8%) Biologic DMARD use^a^61 (51.3%) Not currently receiving DMARDs11 (9.2%) Antihypertensive drugs^b^55 (77.5%)  Diuretic29 (40.8%)  Calcium channel blocker21 (29.6%)  ACE inhibitor19 (26.8%)  β-Blocker18 (25.4%)  Angiotensin II receptor blockers13 (18.3%)  Vasodilator1 (1.4%)  α~2~-Adrenergic agonist1 (1.4%)Laboratory examination results ESR, mm/h21.3 ± 18.3, 14.5 (7--29.2)  \> 15 mm/h45 (37.8%)  ≤ 15 mm/h47 (39.5%)  N/A27 (22.7%) CRP (mg/dl)1.2 ± 2.6, 0.4 (0.2--0.9)  \> 1 mg/dl22 (18.5%)  ≤ 1 mg/dl76 (63.9%)  N/A21 (17.6%)*Abbreviations: BMI* Body mass index, *RA* Rheumatoid arthritis, *RF* Rheumatoid factor, *CCP* Cyclic citrullinated peptide, *DAS28* Disease Activity Score in 28 joints, *CV* Cardiovascular, *DMARD* Disease-modifying antirheumatic drug, *ACE* Angiotensin-converting enzyme, *ESR* Erythrocyte sedimentation rate, *CRP* C-reactive protein, *N/A* Not availableValues are given as number (%), mean ± SD, or median (IQR)^a^ Current use at the time of sampling^b^ Some patients overlap in multiple subcategories

Aberrant [l]{.smallcaps}-arginine metabolism in subjects with RA {#Sec9}
----------------------------------------------------------------

We compared the [l]{.smallcaps}-arginine, [l]{.smallcaps}-arginine catabolic products, and methylated arginine derivatives in patients with RA and age- and sex-matched control subjects (Fig. [2](#Fig2){ref-type="fig"}). Compared with control subjects, the RA cohort had significantly lower levels of [l]{.smallcaps}-arginine (43.2 vs. 71.7 μmol/L, *p* \< 0.001) (Fig. [2a](#Fig2){ref-type="fig"}) and GABR (0.34 vs. 0.70, *p* \< 0.001) (Fig. [2d](#Fig2){ref-type="fig"}). The RA cohort also showed a concomitant increase in the arginase catabolic product [l]{.smallcaps}-ornithine (106.3 vs. 67.6 μmol/L, *p* \< 0.001) (Fig. [2b](#Fig2){ref-type="fig"}) and diminished levels of the NOS catabolic product [l]{.smallcaps}-citrulline (29.6 vs. 35.6 μmol/L, *p* \< 0.001) (Fig. [2c](#Fig2){ref-type="fig"}). In the RA cohort, we also found elevated levels of ADMA (0.76 vs. 0.61 μmol/L, *p* \< 0.001) (Fig. [2e](#Fig2){ref-type="fig"}), SDMA (0.52 vs. 0.46 μmol/L, *p* \< 0.001) (Fig. [2f](#Fig2){ref-type="fig"}), and the index of arginine methylation, ArgMI \[(ADMA+SDMA)/MMA\] (6.2 vs. 5.30, *p* \< 0.001) (Fig. [2h](#Fig2){ref-type="fig"}). Compared with control subjects, plasma level of MMA did not change significantly in patients with RA (0.21 μmol/L in control and RA) (Fig. [2g](#Fig2){ref-type="fig"}).Fig. 2Quantification of [l]{.smallcaps}-arginine and [l]{.smallcaps}-arginine metabolites in human plasma. Plasma levels of [l]{.smallcaps}-arginine and [l]{.smallcaps}-arginine catabolic products and methylated arginine derivatives in patients with rheumatoid arthritis (*n* = 119) vs. control subjects (*n* = 238) were measured using LC-MS/MS: [l]{.smallcaps}-arginine (**a**), [l]{.smallcaps}-ornithine (**b**), [l]{.smallcaps}-citrulline (**c**), GABR (**d**), ADMA (**e**), SDMA (**f**), MMA (**g**), and ArgMI (**h**). *GABR* Global arginine bioavailability ratio (i.e., ratio of [l]{.smallcaps}-arginine to [l]{.smallcaps}-ornithine + [l]{.smallcaps}-citrulline), *ADMA* Asymmetric dimethylarginine, *SDMA* Symmetric dimethylarginine, *ArgMI* Arginine methylation index (i.e., ADMA + SDMA/MMA), *MMA* [l]{.smallcaps}-*N*^G^-monomethyl arginine, *RA* Rheumatoid arthritis. \*\*\* *p* \< 0.001

Next, we performed multivariable logistic regression analysis to estimate the ORs associated with plasma [l]{.smallcaps}-arginine metabolites among the patients with RA. After adjustment for decreased renal function, which influences steady-state level of plasma SDMA in particular \[[@CR22]\], we found that ADMA, SDMA, and ArgMI each had a positive relationship with RA with ORs \>1 (Table [2](#Tab2){ref-type="table"}): ADMA (3.82 \[95% CI, 2.67--5.46\], *p* \< 0.001), SDMA (1.43 \[95% CI, 1.07--1.93\], *p* = 0.0163), and ArgMI (2.0 \[95% CI, 1.50--2.65\], *p* \< 0.001). GABR (OR, 0.03 \[95% CI, 0.01--0.07\], *p* \< 0.001) and [l]{.smallcaps}-arginine (OR, 0.12 \[95% CI, 0.07--0.21\], *p* \< 0.001) each showed a negative relationship with RA. In the general population; both GABR and ArgMI have been shown to be better predictors of major adverse cardiac events than free [l]{.smallcaps}-arginine or individual methylated arginine derivatives \[[@CR20], [@CR23]\]~.~Table 2Elevated [l]{.smallcaps}-arginine metabolites in plasma are associated with rheumatoid arthritis incidenceOR (95% CI)*p* ValueADMA Unadjusted OR3.79 (2.73--5.26)\< 0.001 Adjusted OR3.82 (2.67--5.46)\< 0.001SDMA Unadjusted OR1.68 (1.31--2.16)\< 0.001 Adjusted OR1.43 (1.07--1.93)0.0163ArgMI Unadjusted OR2.03 (1.55--2.65)\< 0.001 Adjusted OR2 (1.5--2.65)\< 0.001GABR Unadjusted OR0.04 (0.02--0.08)\< 0.001 Adjusted OR0.03 (0.01--0.07)\< 0.001[l]{.smallcaps}-arginine Unadjusted OR0.14 (0.09--0.22)\< 0.001 Adjusted OR0.12 (0.07--0.21)\< 0.001[l]{.smallcaps}-ornithine Unadjusted OR7.36 (4.76--11.39)\< 0.001 Adjusted OR7.56 (4.68--12.22)\< 0.001[l]{.smallcaps}-citrulline Unadjusted OR0.55 (0.42--0.71)\< 0.001 Adjusted OR0.38 (0.27--0.53)\< 0.001*Abbreviations: ADMA* Asymmetric dimethylarginine, *SDMA* Symmetric dimethylarginine, *ArgMI* Arginine methylation index (i.e., ADMA + SDMA/[l]{.smallcaps}-*N*^G^-monomethyl arginine), *GABR* Global arginine bioavailability ratio (i.e., ratio of [l]{.smallcaps}-arginine to [l]{.smallcaps}-ornithine + [l]{.smallcaps}-citrulline)Adjusted for age, sex, and decreased renal function (creatinine \> 1.4 mg/dl or GFR ≤ 60 ml/min/1.73 m^2^. ORs are presented per SD

SDMA is associated with hypertension and hyperlipidemia in subjects with RA {#Sec10}
---------------------------------------------------------------------------

We further determined whether the levels of ADMA, SDMA, ArgMI, and GABR were associated with CVD risk factors in patients with RA (Table [3](#Tab3){ref-type="table"}). Among various CVD risk factors, patients with RA with a prior history of hypertension (*n* = 71) showed statistically significant elevated levels of SDMA (μmol/L plasma) compared with patients with RA with normal blood pressure (*n* = 48): (0.6 ± 0.2, 0.5 \[0.5--0.6\]; vs. 0.5 ± 0.1, 0.5 \[0.4--0.5\]; *p* = 0.006). We also found a negative association of SDMA and ArgMI with seropositivity. Plasma SDMA level in seropositive patients with RA (*n* = 85) compared with seronegative patients (*n* = 34) were as follows: 0.5 ± 0.1, 0.5 (0.4--0.6) vs. 0.6 ± 0.2, 0.5 (0.5--0.6) (*p* = 0.035). Similarly, we found a lower ArgMI in seropositive patients compared with seronegative patients: 6.2 ± 1.4, 6.0 (5.3--6.9) vs. 7.6 ± 2.9, 7.3 (6.0--8.8) (*p* = 0.03).Table 3Comparison of plasma levels of [l]{.smallcaps}-arginine metabolites in patients with rheumatoid arthritis with and without cardiovascular risk factorsCV risk factorsADMA (μmol/L)SDMA (μmol/L)ArgMIGABRNo. of patientsValue*p* ValueValue*p* ValueValue*p* ValueValue*p* ValueHistory of diabetes (+)980.8 ± 0.1\
0.8 (0.7--0.8)0.4840.5 ± 0.1\
0.5 (0.4--0.6)0.6526.6 ± 1.9\
6.3 (5.4--7.3)0.0310.4 ± 0.2\
0.3 (0.2--0.4)0.556History of diabetes (−)210.8 ± 0.1\
0.8 (0.7--0.9)0.5 ± 0.1\
0.5 (0.4--0.6)5.9 ± 1.3\
6.1 (5--6.4)0.4 ± 0.2,\
0.4 (0.3--0.5)History of hyperlipidemia (−)630.8 ± 0.1\
0.8 (0.7--0.8)0.2600.5 ± 0.1\
0.5 (0.4--0.6)0.0546.5 ± 2.2\
6.1 (5.3--7.1)0.8500.4 ± 0.2\
0.4 (0.3--0.5)0.259History of hyperlipidemia (+)560.7 ± 0.1\
0.8 (0.7--0.8)0.6 ± 0.2\
0.5 (0.4--0.6)6.5 ± 1.4\
6.5 (5.7--7)0.3 ± 0.2\
0.3 (0.2--0.4)History of HTN (−)480.8 ± 0.1\
0.7 (0.7--0.8)0.6620.5 ± 0.1\
0.5 (0.4--0.5)0.006\*6.3 ± 1.7\
6 (5.3--7.4)0.3460.4 ± 0.1\
0.3 (0.2--0.4)0.875History of HTN (+)710.8 ± 0.1\
0.8 (0.7--0.8)0.6 ± 0.2\
0.5 (0.5--0.6)6.6 ± 2\
6.4 (5.7--7)0.4 ± 0.2\
0.3 (0.3--0.4)Two or more CVD risk factors460.8 ± 0.1\
0.8 (0.7--0.8)0.6400.6 ± 0.2\
0.5 (0.5--0.6)0.1086.5 ± 1.4\
6.4 (5.8--6.9)0.9860.4 ± 0.2\
0.3 (0.3--0.4)0.827Less than two CVD risk factors730.8 ± 0.1\
0.8 (0.7--0.8)0.5 ± 0.1\
0.5 (0.4--0.6)6.5 ± 2.1\
6.1 (5.3--7.3)0.4 ± 0.2\
0.3 (0.2--0.5)Smoking (−)620.8 ± 0.1\
0.7 (0.7--0.8)0.3130.5 ± 0.1\
0.5 (0.4--0.6)0.7546.5 ± 1.6\
6.2 (5.5--7)0.9120.4 ± 0.2\
0.3 (0.2--0.4)0.968Smoking (+)570.8 ± 0.1\
0.8 (0.7--0.8)0.5 ± 0.2\
0.5 (0.4--0.6)6.5 ± 2.2\
6.1 (5.1--7.2)0.4 ± 0.2\
0.3 (0.2--0.4)History of CVD (−)1010.8 ± 0.1\
0.8 (0.7--0.8)0.5420.5 ± 0.1\
0.5 (0.4--0.6)0.3796.6 ± 1.9\
6.2 (5.4--7.3)0.2700.4 ± 0.2\
0.3 (0.2--0.4)0.473History of CVD (+)170.8 ± 0.1\
0.8 (0.7--0.8)0.5 ± 0.1\
0.5(0.4--0.6)6.2 ± 1.2\
6.4 (5--6.7)0.4 ± 0.2\
0.4 (0.2--0.6)Seropositive (+)850.8 ± 0.1\
0.8 (0.7--0.8)0.2930.5 ± 0.1\
0.5 (0.4--0.6)0.0356.2 ± 1.4\
6 (5.3--6.9)0.030.4 ± 0.2\
0.3 (0.3--0.4)0.434Seronegative (−)340.7 ± 0.1\
0.7 (0.7--0.8)0.6 ± 0.2\
0.5 (0.5--0.6)7.6 ± 2.9\
7.3 (6--8.8)0.4 ± 0.2\
0.4 (0.3--0.5)*Abbreviations: ADMA* Asymmetric dimethylarginine, *SDMA* Symmetric dimethylarginine, *ArgMI* Arginine methylation index (i.e., ADMA + SDMA/[l]{.smallcaps}-*N*^G^-monomethyl arginine), *GABR* Global arginine bioavailability ratio (i.e., ratio of [l]{.smallcaps}-arginine to [l]{.smallcaps}-ornithine + [l]{.smallcaps}-citrulline), *CV* Cardiovascular, *CVD* Cardiovascular disease, *HTN* Hypertension

Further, as shown in Table [4](#Tab4){ref-type="table"}, patients in the highest SDMA quartile (≥ 0.58 μmol/L) had a higher prevalence of the following cardiovascular risk factors than those in the lowest quartile (\< 0.44 μmol/L): hypertension (78.8% vs. 44.8%, *p* = 0.039), hyperlipidemia (63.6% vs. 31%, *p* = 0.014) and two or more CV risk factors (54.5% vs. 27.6%, *p* = 0.022). Disease duration, DAS28 scores, and inflammatory markers CRP and ESR were not associated with ADMA, SDMA, ArgMI, or GABR levels (data not shown).Table 4Prevalence of hypertension and hyperlipidemia in patients with rheumatoid arthritis in highest symmetric dimethylarginine quartileSDMA QuartilesQuartile 1Quartile 2Quartile 3Quartile 4*p* ValueNo. of patients29292833SDMA, μM/L\< 0.440.45--0.510.52--0.57≥ 0.58Demographics Age, yr52.8 ± 12.459.7 ± 15.462.5 ± 10.966.7 ± 11.2\< 0.001^a^ BMI, kg/m^2^29.24 ± 6.8327.55 ± 4.7928.55 ± 8.229.67 ± 5.380.592Disease activity Disease duration, yr11.19 ± 9.9113 ± 10.1410.48 ± 7.0511.96 ± 11.020.805 DAS283.47 (2.51--3.9)2.06 (1.38--2.87)2.42 (1.71--2.91)2.76 (1.82--3.63)0.117CV burden and assessments, *n* (%) History of diabetes,5 (17.24%)7 (24.14%)3 (10.71%)6 (18.18%)0.621  History of hyperlipidemia9 (31%)17 (58.6%)9 (32.1%)21 (63.6%)0.014^a^  History of hypertension13 (44.8%)17 (58.6%)15 (53.6%)26 (78.8%)0.039^a^ Two or more CV risk factors8 (27.6%)14 (48.3%)6 (21.4%)18 (54.5%)0.022^a^ History of CVD4 (13.8%)2 (6.9%)5 (17.9%)6 (18.2%)0.585 Smoking14 (48.3%)12 (41.4%)11 (39.3%)20 (60.6%)0.330Laboratory examination results ESR, mm/h14.5 (8.25--28.75)11 (7--30)10 (7--24)21 (9--28.75)0.944 CRP, mg/dl0.6 (0.2--1.7)0.3 (0.2--0.6)0.4 (0.1--1)0.6 (0.2--1.6)0.678*Abbreviations: SDMA* Symmetric dimethylarginine, *BMI* Body mass index, *DAS28* Disease Activity Score in 28 joints, *CV* Cardiovascular, *CVD* Cardiovascular disease, *ESR* Erythrocyte sedimentation rate, *CRP* C-reactive protein^a^ statistically significant

Arginase activity is elevated in RA {#Sec11}
-----------------------------------

We measured plasma arginase activity in 119 patients with RA (Table [1](#Tab1){ref-type="table"}) and compared it with that of 148 age- and sex-matched control subjects. These control subjects had no RA disease activity; however, other clinical parameters of the control subjects were not evaluated. The plasma arginase activity was significantly elevated in the RA cohort (\> 400%) compared with control group (*p* \< 0.0001) (Fig. [3a](#Fig3){ref-type="fig"}).Fig. 3**a** Plasma arginase activity in patients with rheumatoid arthritis (RA) vs. non-RA control subjects. Plasma arginase activity was measured using QuantiChrom Arginase Assay Kit. One unit of arginase converts 1 μmol of [l]{.smallcaps}-arginine to ornithine and urea per minute at pH 9.5 and 37 °C. **b** Elevated arginase activity is associated with RA with prior history of cardiovascular disease (CVD). *p* = 0.048

Further analysis showed heightened arginase activity in a subgroup of 17 patients with RA with existing CVD compared with patients with RA without CVD (*n* = 101) (*p* = 0.048) (Fig. [3b](#Fig3){ref-type="fig"}). Interestingly, elevated arginase activity did not show an association with traditional risk factors such as hypertension, type 2 diabetes, dyslipidemia, and smoking.

Discussion {#Sec12}
==========

Using a comprehensive metabolomic analysis, we tested whether plasma [l]{.smallcaps}-arginine metabolites representing [l]{.smallcaps}-arginine bioavailability and [l]{.smallcaps}-arginine metabolites reflecting NO metabolism were altered in an RA cohort. Compared with healthy control subjects, our RA cohort showed robust increases in the arginase catabolic product [l]{.smallcaps}-ornithine (\~ 60% increase) and diminished NOS catabolic product [l]{.smallcaps}-citrulline (\~ 18% decrease), with a significant decrease in arginine bioavailability (*p* \< 0.001). We also found a 400% increase in plasma arginase activity in patients with RA compared with control subjects.

Several clinical studies have shown that increased arginase activity is associated with endothelial dysfunction in the general population \[[@CR11]\]; however, less is known about the RA population. Arginases are localized in the cytoplasm or in the mitochondria of various cell types, including endothelial cells and immune cells, in particular monocytes/macrophages \[[@CR24], [@CR25]\]. Systemic Inflammatory conditions can increase arginase expression in these cell types \[[@CR26]\]. It is possible that a higher turnover of these cells can cause elevated arginase levels that can be detected in the blood. Arginases are also present in erythrocytes \[[@CR27], [@CR28]\], and perturbation of erythrocytes can release arginases into the circulation. One relatively small study showed that serum arginase activity and arginase protein levels were elevated in patients with RA (*n* = 25) \[[@CR29]\]. Our larger study comparing 119 patients with RA and 148 age- and sex-matched healthy control subjects showed a robust increase in arginase activity along with a reduced level of its substrate, [l]{.smallcaps}-arginine, in the RA plasma.

Our analysis shows no association between increased arginase activity and RA disease activity (DAS28 score). This could be due to a relatively low RA disease activity in our cohort (median DAS28 score, 2.7 \[1.6--3.5\] (Table [1](#Tab1){ref-type="table"}). Alternatively, arginase activity may not elicit a significant effect on the RA pathogenesis per se, but may influence the induction of subclinical endothelial dysfunction in patients with RA. In support of this hypothesis, Prati et al. showed that a specific arginase inhibitor restores endothelial function without ameliorating disease activity in an acute rat model of arthritis \[[@CR30]\]. Interestingly, the disconnect was further supported by our observation that seronegative subjects had statistically significant elevated levels of SDMA and ArgMI compared with seropositive patients (Table [3](#Tab3){ref-type="table"}), although the latter showed higher extraarticular disease manifestations. The disconnect between arginase activity and RA disease activity could have clinical implications because arginase activity can be a biomarker of increased CVD risk independent of the patient's disease state.

Negative regulation of NO synthesis can also be mediated via overproduction of methylated arginine analogues such as MMA, ADMA, and SDMA. Among the methylated derivatives, ADMA, a potent endogenous inhibitor of NOS and a marker of endothelial dysfunction, has been shown by our group and others to serve as an independent risk factor for cardiovascular events in the general population \[[@CR14], [@CR16]\]. Multiple studies show that ADMA levels were significantly elevated in patients with RA compared with control subjects \[[@CR31]--[@CR34]\]. However, Sandoo et al, showed a lack of association microvascular and macrovascular endothelial function in patients with rheumatoid arthritis \[[@CR35]\]. Further, a recent study showed that ADMA levels were inversely correlated with flow-mediated dilation in patients with RA \[[@CR15]\]. Erre et al. showed that ADMA is not associated with arterial stiffness in patients with RA \[[@CR36]\]. These findings are in agreement with another study that showed supplementation of tetrahydrobiopterin, a cofactor for the production of NO, improved endothelial function but failed to improve aortic stiffness \[[@CR37]\]. Our study shows that plasma ADMA is significantly elevated in patients with RA compared with control subjects; in future larger studies, we will include endothelial function and determine the relationship of ADMA/SDMA and endothelial function in an RA group.

In our study, levels of SDMA were also significantly elevated in patients with RA (*p* \< 0.001). An elevated SDMA in patients with RA level is associated with an adjusted OR of 1.43 (1.07--1.93, *p* = 0.0163). However, one group showed a decrease in SDMA level in patients with RA compared with control patients and an inverse correlation between SDMA level and microvascular function \[[@CR38], [@CR39]\]. The same group also showed that SDMA levels in patients with RA were independent of cumulative inflammatory burden and that there was no association with cardiovascular risk factors, including hypertension \[[@CR40]\]. This discrepancy in comparative levels of SDMA in patients with RA between the two studies may be due to multiple factors, including differences in subject age, disease activity, and extent of comorbid renal disease, as well as, more important, divergent techniques used in the measurement of SDMA in the plasma.

Although ADMA is emerging as a biomarker of CVD, the implications of elevated circulating SDMA are not well understood. Recent reports, including our group's, have shown an association between elevated plasma SDMA levels and higher mortality in patients with CVD \[[@CR17]--[@CR19]\]. It has been shown that association of SDMA with CVD risk factors, in particular with hypertension, may arise from compromised renal function \[[@CR17]--[@CR19]\], given that SDMA is eliminated by renal excretion and has been shown to be a marker of estimated glomerular filtration rate \[[@CR22]\]. However, multivariable logistic regression analysis (Table [3](#Tab3){ref-type="table"}), adjusted for glomerular filtration rate and plasma creatinine level, demonstrated that elevated SDMA was associated with hypertension in the RA cohort independent of renal function. SDMA interquartile analysis (Table [4](#Tab4){ref-type="table"}) further demonstrated that patients in the highest SDMA quartile had a significantly higher prevalence of hypertension and hyperlipidemia than those in the lowest SDMA quartile. ADMA, ArgMI, and GABR, which have recently emerged as candidate biomarkers of CV risk \[[@CR14], [@CR16], [@CR18], [@CR20], [@CR23]\], failed to show significant changes in any of the traditional CVD risk factors analyzed. Our results suggest that SDMA potentially functions as a biomarker of cardiovascular risk factors in RA. More studies are needed to gain an understanding of the underlying mechanisms that link SDMA specifically to hypertension and hyperlipidemia in patients with RA.

Study limitations {#Sec13}
-----------------

One limitation of this study is the relatively small sample size, which may limit the statistical power of the conclusions. We did not evaluate the population characteristics, other than age, sex, and disease activity, in the control population. Also, this was a single-center study using a cross-sectional evaluation of biomarkers. Because this study did not use fasting blood samples, it is possible that plasma levels of arginine and its metabolic products were influenced by food intake. Further, medical interventions that might have the potential to alter plasma [l]{.smallcaps}-arginine metabolites were not considered. No direct physiologic vascular measures were taken to directly link dysfunctional arginine metabolism to vascular functional changes and potential cardiovascular risks. We also acknowledge that, other than arginases and NOS, levels of [l]{.smallcaps}-arginine, [l]{.smallcaps}-citrulline, and [l]{.smallcaps}-ornithine can be altered by the aberrant release/uptake of these molecules in and out of the circulation and dysregulation of enzymes that participate in their biosynthesis \[[@CR10]\]. We did not measure these parameters in our study. Nevertheless, our studies point to the importance of understanding NO synthesis-related dysfunctional [l]{.smallcaps}-arginine metabolic pathways in RA that may provide novel therapeutic and prophylactic approaches to improve vascular health and thereby reduce CVD risk in patients with RA and related rheumatic diseases.

Conclusions {#Sec14}
===========

We performed a comprehensive analysis of plasma [l]{.smallcaps}-arginine metabolic products and methylated arginine derivatives in a cohort of patients with RA and control subjects. We identified diminished global [l]{.smallcaps}-arginine availability and decreased levels of the NOS catabolic product [l]{.smallcaps}-citrulline, whereas levels of both arginase activity and its catabolic product [l]{.smallcaps}-ornithine were elevated in plasma of patients with RA. Additionally, we found increased levels of endogenous inhibitors of NO production ADMA and SDMA in the plasma of patients with RA. Further, plasma SDMA levels were associated with cardiovascular risk factors, hypertension, and hyperlipidemia, whereas elevated arginase activity was associated with prior history of CVD in a subgroup of patients with RA. Our study suggests that increased ArgMI and diminished global arginine bioavailability with concomitant elevated arginase activity in plasma can potentially predict CVD risk in patients with RA. Additional controlled longitudinal studies are required to establish the importance of these pathways in the development of atherosclerosis and cardiac diseases in patients with RA.
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